rs121434247
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PP3PP5_Very_Strong
The ENST00000622030.2(SRD5A2):c.547G>A(p.Gly183Ser) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000267 in 1,575,150 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
ENST00000622030.2 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SRD5A2 | NM_000348.4 | c.547G>A | p.Gly183Ser | missense_variant, splice_region_variant | 3/5 | ENST00000622030.2 | NP_000339.2 | |
SRD5A2 | XM_011533069.3 | c.325G>A | p.Gly109Ser | missense_variant, splice_region_variant | 3/5 | XP_011531371.1 | ||
SRD5A2 | XM_011533072.3 | c.292G>A | p.Gly98Ser | missense_variant, splice_region_variant | 5/7 | XP_011531374.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SRD5A2 | ENST00000622030.2 | c.547G>A | p.Gly183Ser | missense_variant, splice_region_variant | 3/5 | 1 | NM_000348.4 | ENSP00000477587 | P1 | |
ENST00000435713.1 | n.255+3671C>T | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 152168Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000310 AC: 6AN: 193796Hom.: 0 AF XY: 0.0000388 AC XY: 4AN XY: 103180
GnomAD4 exome AF: 0.0000141 AC: 20AN: 1422982Hom.: 0 Cov.: 29 AF XY: 0.0000114 AC XY: 8AN XY: 704272
GnomAD4 genome AF: 0.000145 AC: 22AN: 152168Hom.: 0 Cov.: 32 AF XY: 0.000135 AC XY: 10AN XY: 74326
ClinVar
Submissions by phenotype
3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Biochemistry Laboratory, Health Services Laboratory | Nov 20, 2023 | ACMG:PS5 PM2 PM3 PP4 PP5 - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 183 of the SRD5A2 protein (p.Gly183Ser). This variant also falls at the last nucleotide of exon 3, which is part of the consensus splice site for this exon. This variant is present in population databases (rs121434247, gnomAD 0.04%). This missense change has been observed in individual(s) with steroid 5-alpha-reductase deficiency (PMID: 1522235, 18314109, 18350250, 28544750). ClinVar contains an entry for this variant (Variation ID: 3341). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this missense change affects SRD5A2 function (PMID: 18350250). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital | Sep 23, 2013 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 1996 | - - |
SRD5A2-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 28, 2024 | The SRD5A2 c.547G>A variant is predicted to result in the amino acid substitution p.Gly183Ser. This variant has been reported in the homozygous and compound heterozygous state in multiple individuals with steroid 5-alpha-reductase deficiency (S5ARD) and has been reported in both sporadic cases and in individuals with a family history of S5ARD (Thigpen et al. 1992. PubMed ID: 1522235; Cai et al. 1996. PubMed ID: 8626825; Sahakitrungruang et al. 2008. PubMed ID: 18314109; Liu et al. 2022. PubMed ID: 35700942; Milewich et al. 1995. PubMed ID: 7593415; Hackel et al. 2005 PubMed ID 15770495; Table S5, Gomes et al. 2022. PubMed ID: 35134971). In vitro experimental studies show this variant affects the catalytic activity of the enzyme by decreasing its affinity for testosterone substrate, with a residual activity ~12% compared to control (Wigley et al. 1994. PubMed ID: 8110760; Vilchis et al. 2008. PubMed ID: 18350250). This variant is reported in ~0.050% of alleles in individuals of African descent in gnomAD, and has been described as a founder variant in individuals of Brazilian and Domican ancestry (Hackel et al. 2005 PMID 15770495). This variant has been classified as pathogenic by multiple clinical labs in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/3341/). Taken together, we classify this variant as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at